Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context
Recruiting · NCT07621783 · Observational (researchers observe without assigning treatment) · Lead sponsor: Imelda GI Clinical Research Center
View the official record on ClinicalTrials.gov →Interventions studied
Leucine-rich α2-glycoprotein
What this trial is about
Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.
Who can take part
Age range
16 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- ≥18 years
- Patient with confirmed diagnosis of IBD
- Patient with planned endoscopy (ileocolonoscopy for Crohn's disease (CD)/ulcerative colitis (UC) or sigmoidoscopy for UC) for the assessment of endoscopic disease activity according to routine practice
- willing to provide informed consent
Exclusion criteria
- Patient with IBD unspecified
- Patient with ileo- or colostomy
- Patient with total colectomy
- Women that are pregnant
Where it is running
2 locations listed.
- Imelda General Hospital - Bonheiden, Belgium
- Imelda General Hospital - Bonheiden, Belgium